Today's Sponsored Feature is part of your subscription to AdvaMed SmartBrief. This feature, produced by SmartBrief and a select group of sponsors, highlights issues, products and services of interest to the medical technology industry. It also allows for continued free delivery of AdvaMed SmartBrief. Thank you for your interest.

                                                                                                                                     - The AdvaMed SmartBrief Team

SPONSORED FEATURE
BSI's Featured White Paper
ISO 13485 and CE Marking
Effective Post-Market Clinical Follow-Up

Dr. Hamish Forster, BSI's Orthopedic & Dental Product Expert, released “The Post-Market Priority,” a white paper that provides a detailed overview of how the recent EU revisions will affect post-market clinical planning and the working relationship with a Notified Body.

To receive a complimentary copy, please:

Request a copy

Certification is a Journey, Not Just a Destination

The first step of the certification journey begins with ISO 13485. The standard is an effective solution to meet quality management system (QMS) requirements. Adopting ISO 13485 also provides the foundation needed to meet CE Marking requirements.

Demonstrate your commitment to patient safety, and Begin Your Journey Today

BSI Healthcare Profile
Since 1901, BSI has provided customers with impartial third-party standards-based assurance, compliance, information solutions, and training. BSI is a trusted partner to Industry and Government with over 66,000 organizations, in almost 150 countries, working with over 50 BSI global offices. Our mission is to ensure patient safety while supporting timely access to global medical device technology. We provide thorough, responsive, predictable conformity assessments, evaluations, and certifications that are recognized and accepted worldwide.

For more information on BSI Healthcare, please:

Visit: www.bsiamerica.com/healthcare
Email: healthcare@bsigroup.com
Contact: 1-888-429-6178
Follow Us: twitter.com/bsiamerica
Resource Center
Complimentary Webinar
Post-Market Surveillance and Vigilance

Post-market surveillance including clinical follow-up, complaints, and vigilance are vital in ensuring compliance with the EU medical device directives and are an essential component of a 13485 QMS. Learn how to identify the requirements of the European medical device directives, standards, and guidance documents needed to implement an effective post-market surveillance system.

Register Today
SmartBrief Archives: Related News
  • FDA issues draft guidance on post-approval drug safety
    The FDA is seeking public comment on guidance detailing a system for handling postmarket drug safety issues, including drug quality and serious adverse events. The draft guidance establishes a three-tiered system of classifying the severity of problems. PMLive.com (U.K.) (3/12)
  • FDA completes guidelines on continuing clinical trial reviews
    The FDA has issued final guidelines on performing continuing reviews to ensure the safety of participants in medical device and drug trials. The guidance, which is based on a proposal issued for public comment in January 2010, also details the type of information that institutional review boards should require from clinical trial sponsors or researchers. Clinica (subscription required) (3/6)
  • FDA issues guidance on submitting electronic trial data
    The FDA has issued guidance on the electronic submission of standardized trial data for medical devices. The document includes guidelines on planning and providing standardized information, terminology, handling data that can't be standardized, validation of data and meetings with the FDA. MassDevice.com (Boston) (2/22)
  • Task force seeks comments on IVD device evaluation proposal
    The Global Harmonizaton Task Force has issued proposed guidelines designed to help companies undertake clinical performance evaluations for their in vitro diagnostic devices. The proposal, which includes factors to consider when performing such studies as well as trial design choices based on IVD product types and indications, is up for comment through June 2. Clinica (subscription required) (2/21)
What is this?A Sponsored Feature is an advertorial that includes valuable content provided by the sponsor and editorial materials from SmartBrief's archives. This Sponsored Feature does not represent an endorsement by the ADVAMED or SmartBrief, Inc. of the products and services offered. If you unsubscribe from this Sponsored Feature, you will not be unsubscribing from all other editions of the AdvaMed SmartBrief.
Subscriber Tools:
Sign up for AdvaMed SmartBrief | Send Feedback | Email this brief | Unsubscribe from AdvaMed SmartBrief Sponsored Features
Advertising with SmartBrief:Sales Account Director: Meryl Harold (202) 407-7828
Mailing Address:SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.®  Legal Information.